Genomic and gene expression-based characterizations have resulted in improved molecular subtyping of lung cancer and identification of driver mutations including epidermal growth factor receptor (EGFR-10–30%), Kirsten rat sarcoma viral oncogene homolog (KRAS-15–30%), and fibroblast growth factor receptor 1 (FGFR1-20%), among others [4, 5]. Here, EGFR is linked to lung carcinoma.